Background: Molnupiravir, N4-hydroxycytidine-5'-isopropyl ester, is an oral prodrug of N4-
deoxycytidine (NHC), a nucleoside analog, which has in vitro activity against SARS-CoV-2 …

Background: Molnupiravir is a ribonucleoside analog and exhibits its antiviral mechanism by
inhibiting replication. Preclinical studies have been reported that support the role of …

Molnupiravir (EIDD-2801/MK-4482) is a prodrug for the ribonucleoside analogue β-d-N4-
hydroxycytidine (NHC; EIDD-1931), which has been shown to be useful in the treatment of …

The nucleoside analog β-D-N4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
pandemic, several treatments have been proposed to cure coronavirus disease 2019 …

Abstract SARS-CoV-2, the virus responsible for COVID-19, has caused numerous deaths
worldwide and poses significant challenges. Researchers have recently studied a new …

Background The study was aimed at encapsulating the evidence of in vitro and in vivo
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …

Background: Molnupiravir, an orally administered prodrug of the broadly active, direct-acting
antiviral, ribonucleoside analogue ß-d-N4-hydroxycytidine (NHC) is a promising COVID-19 …

The nucleoside analog N4-hydroxycytidine (NHC) is the active metabolite of the prodrug
molnupiravir, which has been approved for the treatment of COVID-19. SARS-CoV-2 …